Liu Jia-Ru, Szigiato Andrei-Alexandru, Harasymowycz Paul
Department of Ophthalmology, University of Montreal, Quebec H3T 1J4, Canada.
Department of Ophthalmology, Hôpital Sacré-Coeur, Quebec H4J 1C5, Canada.
Int J Ophthalmol. 2025 Jan 18;18(1):79-85. doi: 10.18240/ijo.2025.01.09. eCollection 2025.
To assess visual outcomes and satisfaction of a non-diffractive extended depth of focus (EDOF) intraocular lens (IOL) in individuals with ocular hypertension (OHT) and well-controlled mild glaucoma undergoing cataract surgery.
An investigator-initiated, single-center, prospective, interventional, noncomparative study conducted in Montreal, Canada. The study enrolled 31 patients (55 eyes) with OHT or mild glaucoma who received a non-diffractive EDOF IOL (Acrysof IQ Vivity). Participants underwent sequential cataract surgery with the Vivity IOL. Follow-up evaluations occurred at 1d, 1, and 3mo postoperatively, assessing uncorrected distance, intermediate, and near visual acuity. Questionnaires (QUVID: Questionnaire for visual disturbances and IOLSAT: Intraocular lens satisfaction) were administered pre and post-operatively to measure visual disturbances and spectacle independence in various lighting. Safety parameters included intraocular pressure (IOP), glaucoma medications, spherical equivalence, mean deviation and pattern standard deviation or square root of lost variance on Octopus visual field.
At 1 and 3mo postoperatively, significant improvements were observed in uncorrected distance and intermediate visual acuity. Spectacle independence was enhanced for distance and intermediate vision, especially in bright light settings. Spectacle-free intermediate vision was improved even in dim lighting. Visual disturbances, particularly glare symptoms, were reduced, and there was a notable decrease in IOP and glaucoma medication burden at 3mo. There was more hazy vision postoperatively with no impact on visual acuity and visual satisfaction.
The non-diffractive EDOF lens improves distance and intermediate spectacle-free visual function in patients with OHT and well-controlled glaucoma. The findings highlight significant improvements in visual acuity, reduced glare, enhanced spectacle independence, and improved visual performance in different lighting conditions.
评估非衍射型扩展景深(EDOF)人工晶状体(IOL)在接受白内障手术的高眼压症(OHT)患者和病情得到良好控制的轻度青光眼患者中的视觉效果和满意度。
在加拿大蒙特利尔进行的一项由研究者发起的单中心、前瞻性、干预性、非对比性研究。该研究纳入了31例(55只眼)患有高眼压症或轻度青光眼的患者,他们接受了非衍射型EDOF人工晶状体(Acrysof IQ Vivity)。参与者接受了使用Vivity人工晶状体的连续性白内障手术。术后1天、1个月和3个月进行随访评估,评估未矫正的远、中、近视力。术前和术后发放问卷(QUVID:视觉干扰问卷和IOLSAT:人工晶状体满意度问卷),以测量不同光照条件下的视觉干扰和摆脱眼镜依赖的情况。安全参数包括眼压(IOP)、青光眼药物使用情况、球镜等效度、平均偏差以及Octopus视野上的模式标准偏差或丢失方差的平方根。
术后1个月和3个月时,未矫正的远视力和中视力有显著改善。远视力和中视力的摆脱眼镜依赖情况得到改善,尤其是在明亮光线下。即使在昏暗光线下,无眼镜的中视力也有所提高。视觉干扰,特别是眩光症状有所减轻,并且在3个月时眼压和青光眼药物负担显著降低。术后有更多视物模糊的情况,但对视力和视觉满意度没有影响。
非衍射型EDOF人工晶状体可改善高眼压症和病情得到良好控制的青光眼患者的远视力和中视力无眼镜视觉功能。研究结果突出了视力的显著改善、眩光减少、摆脱眼镜依赖增强以及在不同光照条件下视觉性能的提高。